Westlake Aging Cohort (WeAC)
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age55-90
SponsorWestlake University
About this trial
The Westlake Ageing Cohort (WeAC) is a longitudinal cohort study conducted in Hangzhou, Zhejiang Province, China. The investigators aim to enroll 2,800 participants aged 55 years and older for long-term follow-up. The population will include individuals with neurodegenerative diseases or those at the prodromal stage of cognitive impairment, as well as healthy middle-aged and older adults serving as controls. The investigators will collect their sociodemographic, dietary, lifestyle, clinical, and neuroimaging data, as well as biological samples.
Eligibility criteria
Qualifiers
Age between 55 and 90 years (inclusive) at baseline.
Availability of a companion capable of providing independent functional assessments and fluent in Chinese.
Willingness and ability to regularly complete required surveys and physical examinations as per study protocol.
MMSE scores were required to be 24-30 (inclusive) for healthy controls and MCI; and 20-24 (inclusive) for AD and DLB/PDD patients.
Disqualifiers
Participants with major medical or neuropsychiatric conditions unrelated to the study purposes were excluded. These included, but were not limited to, psychiatric disorders, cancer, infectious diseases, structural brain abnormalities, and epilepsy.
Current use of psychoactive medications or any other drugs that may affect the study.
Participants with cardiac pacemakers, artificial heart valves, or metallic implants in the eyes, skin, or any other part of the body.
Participants with any other diseases that may affect the study.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Westlake University
Lead sponsor
Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University
Collaborator
The Third People's Hospital of Hangzhou
Collaborator
Source ClinicalTrials.gov